Dordaviprone not checked
Jazz Pharmaceuticals · ONC201 · TIC10
FollowEvery change as it happens, and a Monday email
Trials
1 active
8 in total · 2 in the EU
What this is
- How it works
- Protease Activator FDA class
- How it’s given
- “Participants ≥ 52.5 kg will receive 625 mg of dordaviprone (5 × 125-mg capsules) or matching placebo on dosing days; participants \< 52.5 kg will receive a dose (and corresponding number of capsules) scaled by body weight and rounded to 125-mg increments”In the company’s words, NCT05580562 on ClinicalTrials.gov
- Tested for
- H3 K27M, Glioma
- Main trialPhase 3
- “This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.”In the company’s words, NCT05580562 on ClinicalTrials.gov
- Other names
- ONC201 · TIC10
Other drugs for Glioma
- 5-Aminolevulinic Acid Hydrochloride PowderLee's Pharmaceutical Limited · Phase 3
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- LAM561Laminar Pharmaceuticals · Phase 2/3
Coming up1
- Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jun 2028 | ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | |
| Phase 2Terminated | 31 Dec 2022 | ONC201 in Adults With Recurrent H3 K27M-mutant Glioma | |
| Phase 2Terminated | 19 Jan 2023 | ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer | |
| Phase 2Terminated | 17 Apr 2023 | Oral ONC201 in Adult Recurrent Glioblastoma | |
| Phase 1/2Withdrawn | Dec 2015 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | |
| Phase 1/2Terminated | 17 Sep 2019 | Oral ONC201 in Relapsed/Refractory Multiple Myeloma | |
| Phase 1Terminated | 31 Dec 2022 | ONC201 in Pediatric H3 K27M Gliomas | |
| Phase 2Halted | not given | PNOC022: A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026